Predictors of Formaldehyde-related Adverse Symptoms Among Laboratory Users in a University in Malaysian Borneo.

Pain is among the most debilitating symptoms in cancer patients, affecting approximately 55% of those undergoing active treatment and up to 66–80% at advanced disease stages []. The World Health Organization (WHO) analgesic ladder, first introduced in 1986 and subsequently revised, positions opioids as the cornerstone of moderate-to-severe cancer pain management []. Yet clinical practice consistently demonstrates that opioid therapy is far from uniform: substantial interindividual variability exists in analgesic efficacy, opioid dose requirements, and the incidence and severity of adverse effects including nausea, constipation, sedation, cognitive impairment, and respiratory depression. Twin studies estimate that genetic factors account for a significant proportion of the variability in opioid response, although the magnitude varies substantially depending on the phenotype measured: genetic effects explain 12–60% of the variance in pain sensitivity and analgesic response to opioid agonists, with the highest heritability observed for cold-pressor pain tolerance (49% at baseline, 60% for opioid-mediated threshold elevation) and lower estimates for heat pain responses (12%) [,]. This observation has driven intensive pharmacogenomic research grounded in the candidate-gene paradigm: selecting genes known or hypothesized to influence opioid pharmacodynamics or pharmacokinetics, and testing whether common polymorphisms are associated with measurable clinical outcomes. The genes investigated span the entire pharmacological pathway—from the receptor itself to the enzymes that metabolize the drug, the transporters governing bioavailability and tissue distribution, and downstream signalling molecules. Despite the scientific plausibility of this framework, accumulated evidence has been disappointing [,,]. Furthermore, the tumour itself—through the microenvironment, neuroimmune signalling, metabolic reprogramming, and cancer-induced organ dysfunction—imposes a layer of biological interference that profoundly modifies both pharmacogenomic signals and opioid pharmacology in ways rarely accounted for in published studies. This review addresses both dimensions. Exogenous opioids exert their effects by binding to G protein-coupled receptors classified into three major subtypes, mu (MOR, encoded by *OPRM1*), delta (DOR, encoded by *OPRD1*), and kappa (KOR, encoded by *OPRK1*), together with the structurally related nociceptin/orphanin FQ receptor (NOP/ORL1, encoded by *OPRL1*) []. All clinically used analgesic opioids—morphine, oxycodone, hydromorphone, fentanyl, buprenorphine, and methadone—exert their primary analgesic action through the mu receptor. MOR activation inhibits adenylate cyclase, reduces voltage-gated calcium channel conductance, and opens inwardly rectifying potassium channels, collectively reducing neuronal excitability at supraspinal and spinal nociceptive circuits [,]. Agonist-induced receptor desensitization, internalization, and recycling—processes underpinning analgesic tolerance—are ligand- and context-specific. These processes are influenced by the receptor’s primary sequence and interacting proteins, providing molecular rationale for investigating receptor-coding polymorphisms.